SCHEMBL4201216

SCHEMBL4201216

CCOc1cc(Nc2c(C#N)cncc2-c2ccc(OC)c(OC)c2)c(Cl)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 19/20 0.71
SRC P12931 1/20 0.63
PRKCD Q05655 5/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180885 0.93 PRKCQ (0.69) PRKCQSRCPRKCD
SCHEMBL4201189 0.92 PRKCQ (0.79) PRKCQPRKCD
SCHEMBL4182625 0.92 PRKCQ (0.68) PRKCQSRCPRKCD
SCHEMBL4191857 0.91 PRKCQ (0.69) PRKCQPRKCD
SCHEMBL4182391 0.87 PRKCQ (0.66) PRKCQSRCPRKCD
SCHEMBL4189354 0.87 PRKCQ (0.66) PRKCQSRCPRKCD
SCHEMBL4196660 0.83 PRKCQ (1.00) PRKCQSRCPRKCD
SCHEMBL4190270 0.83 PRKCQ (1.00) PRKCQSRCPRKCD
SCHEMBL4183410 0.82 PRKCQ (0.83) PRKCQSRCPRKCD
SCHEMBL4189108 0.81 PRKCQ (0.90) PRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027093-A2 SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS Wyeth (US) 2009-02-25 EP claimed
WO-2007146323-A2 SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2007-12-21 WO claimed
US-20070287738-A1 Substituted Cyanopyridines as protein kinase inhibitors WYETH 2007-12-13 US claimed
US-20070287738-A1 Substituted Cyanopyridines as protein kinase inhibitors WYETH 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287738-A1 Substituted Cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K6 PRKCQ 166/4885SRC 797/4885PRKCD 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.